Munich, Germany – Formycon AG (FWB: FYB) today announced that its commercialization partner, Coherus BioSciences, Inc. has released new sales figures for CIMERLI®1 (Ranibizumab-eqrn) in the US.  Accordingly, the number of CIMERLI® doses sold since its commercial launch in the US in October 2022 has increased to around 190,000 by the end of 2023. In October 2023, the number of doses sold was reported at 100,000. Thus, the amount almost doubled in the fourth quarter of 2023. According to Coherus, cumulative sales of CIMERLI® in the US totaled USD 125 million, exceeding original expectations by around 25%.2 Formycon benefits from net sales in the low double-digit million range, which are reflected partly in sales and partly in the at-equity result of the 50% participation in Bioeq AG.

CIMERLI® is the first FDA-approved Lucentis®3-biosimilar for both strengths. In December 2023, CIMERLI® achieved a market share of 38% by volume in the US Ranibizumab market4 and thereby continues to be the most successful biosimilar in this segment.

„We are extremely pleased with the successful uptake of our Lucentis® biosimilar in the US, which has continued to gain momentum from quarter to quarter. The figures are similarly positive in the UK, where FYB201 (trade name: Ongavia®5) achieved a market share of 69% in November 2023.6 This is confirmation of the outstanding quality of our biosimilar and the strong performance of our commercialization partners. With recent approvals in Canada, among others, and subsequent expected approvals and launches in Latin America, the Middle East and North Africa, we see how this highly important treatment option in the field of ophthalmology reaches more and more markets and can contribute to the best possible care for patients,“ commented Dr. Stefan Glombitza, CEO of Formycon AG.

1)CIMERLI® is a registered Trademark of Coherus BioSciences, Inc.
2)Preliminary, unreviewed and unaudited financial information of Coherus BioSciences, Inc.
3) Lucentis® is a registered Trademark of Genentech Inc
5)Ongavia® is a registered trademark of Teva Pharmaceutical Industries Ltd.
6)IQVIA Monthly Data